I hope to foster a culture of science with NIBR that is open, entrepreneurial, and collegial, unwilling to accept barriers or conventional wisdom, and will establish incentives matched to that spirit.

Mark C. Fishman, M.D., Former President, NIBR

NIBR

Novartis Institutes for BioMedical Research is the global pharmaceutical research organization for Novartis. The NIBR research network is comprised of more than 6,000 scientists, physicians and business professionals working together across nine locations worldwide to discover innovative medicines that treat diseases with high unmet medical need.

NIBR’s mission is to focus on diseases where the mechanism is known and where there is great medical need. We also seek to change the practice of medicine by developing/using novel research approaches and tools to discover truly innovative drugs.

Rare diseases are a key strategic focus of the research strategy at NIBR, where scientists are currently investigating treatments for more than 40 rare diseases.

We choose to work where there is unmet need and where the scientific understanding is strongest.

Mark C. Fishman, M.D., Former President, NIBR

Novartis is consistently rated as having one of the industry’s most respected development pipelines, with more than 200 projects in clinical development, including 145 in the Pharmaceuticals Division, as of April 21, 2016. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide.

NIBR is committed to creating a culture of learning that fosters scientific innovation and interdisciplinary research, while also instilling a culture of mentoring to support excellence across the organization. We promote innovation by endorsing inclusion and the connection of diverse ideas, individuals, and teams.

Our Cambridge site is the NIBR global headquarters. Novartis employs more than 2,000 associates in Cambridge, making it the city’s largest private employer and ideally situated in one of the leading life science communities in the world.

For more information about NIBR, please visit http://www.nibr.com. Questions or comments may be directed to NIBRIT.staffing@novartis.com.


Novartis

Novartis focuses on innovative pharmaceuticals and oncology medicines, generics and biosimilars, and eye care. We use science-based innovation to address some of society’s most challenging healthcare issues. We aim to lead in growing areas of healthcare where innovation can make a meaningful difference for patients and society. Our company has three focused, customer facing divisions: Innovative Medicines, including the Novartis Pharmaceuticals and Novartis Oncology units, Sandoz, and Alcon.

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented, performance driven people. All of which makes us one of the most rewarding employers in our field. Our company culture is guided by high ethical standards. Our values help guide the choices people make every day, and they define our culture and help us execute the Novartis strategy in line with our mission and vision: Innovation, Quality, Collaboration, Performance, Courage, and Integrity.

With world headquarters in Basel, Switzerland, Novartis has offices throughout Europe, North America, and Asia.

For more information about Novartis, please visit http//www.novartis.com/

We apply our expertise in science and innovation to society’s biggest health challenges. We take our role in improving health seriously and focus on areas where we can lead and make a significant impact.

Joseph Jimenez, Chief Executive Officer, Novartis